A Randomized, Open-Label, Multicenter, Global Phase 2 Study...

International Journal of Radiation Oncology*Biology*Physics 2018 / 04 Vol. 100; Iss. 5

A Randomized, Open-Label, Multicenter, Global Phase 2 Study of Durvalumab (D), Tremelimumab (T), or D Plus T, in Patients With PD-L1 Low/Negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: CONDOR

Siu, L., Even, C., Mesía, R., Daste, A., Krauss, J., Saba, N.F., Nabell, L., Ready, N.E., Garcia, I.Brana, Kotecki, N., Zandberg, D.P., Gilbert, J., Mehanna, H., Jarkowski, A., Melillo, G., Armstrong,
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
100
Language:
english
Journal:
International Journal of Radiation Oncology*Biology*Physics
DOI:
10.1016/j.ijrobp.2017.12.021
Date:
April, 2018
File:
PDF, 172 KB
english, 2018
Conversion to is in progress
Conversion to is failed